(Q38747416)

6 September 2017

Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? (English)

1 reference

6 September 2017

1 reference

Jose C Florez

1

1 reference

6 September 2017

10 March 2017

1 reference

6 September 2017

1 reference

6 September 2017

60

1 reference

6 September 2017

5

1 reference

6 September 2017

800-807

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-017-4227-1

6 September 2017

0 references

cites work

Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The pharmacogenetics of type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Pharmacogenetics in type 2 diabetes: potential implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Activating mutations in the ABCC8 gene in neonatal diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

A clinical trial to maintain glycemic control in youth with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

An update on the pharmacogenomics of metformin: progress, problems and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Metformin pharmacogenomics: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Leveraging Genetics to Advance Type 2 Diabetes Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

A map of open chromatin in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Molecular mechanism of action of metformin: old or new insights?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4227-1

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28283684

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28283684

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28283684

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-017-4227-1

1 reference

PubMed ID

28283684

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

28283684